Aurora Spine's Q1 gross margin improves on higher direct sales

Aurora Spine

28/05/2026 12:24

Overview
U.S. spinal implant maker's fiscal Q1 revenue rose 0.4% yr/yr on higher biologics, lumbar sales
Gross profit margin improved to 62.6% from 58.0% on more direct sales
Net loss narrowed yr/yr as higher margins and expense controls offset flat sales

Outlook
Aurora expects sales of DEXA-branded products to build throughout 2026
Company anticipates flat or slightly lower results in Q2 as sales team improvements continue
Gross profit margin expected to remain at improved levels due to more direct sales

Result Drivers
DIRECT SALES MIX - Higher gross profit margin driven by increased direct sales of proprietary products, per CEO and CFO
BIOLOGICS LAUNCH - Launch of Aurora Biologics division led to 124% increase in biologics sales yr/yr
LUMBAR AND ZIP IMPLANTS - Increased activity in the pain market, with higher lumbar and Zip implant sales, drove revenue

Company press release: ID:nGNXVJJjb

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Operating Expenses
 
$2.98 mln
 

Analyst Coverage
The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)